Alkermes plc (ALKS)

24,07 +0,22 (+0,92%) Alla chiusura: 04:00PM EDT

Alkermes plc

Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 2.100

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard F. Pops	Chairman & CEO	2,61M	N/D	1962
Mr. Blair C. Jackson	Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO	1,17M	N/D	1973
Mr. David Joseph Gaffin	Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary	1,15M	N/D	1972
Mr. Iain Michael Brown	Senior VP & CFO (Leave of Absence)	950,88k	N/D	1969
Dr. Craig C. Hopkinson M.D.	Executive VP of Research & Development and Chief Medical Officer	1,24M	N/D	1968
Dr. Floyd E. Bloom M.D.	Founder	57,73k	N/D	1937
Mr. Samuel J. Parisi	Interim Principal Accounting Officer & VP of Finance	N/D	N/D	1975
Mr. Thomas Harvey	Chief Information Officer & Senior VP of IT	N/D	N/D	N/D
Ms. Sandra Coombs	Senior Vice President of Corporate Affairs & Investor Relations	N/D	N/D	N/D
Mr. Stephen Schiavo	Senior Vice President of Human Resources	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Alkermes plc al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.